FDA Panel Accepts Metreleptin For Generalized Lipodystrophy, No Further Criteria Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
Members of the Endocrinologic and Metabolic Drugs Advisory Committee say there is no data to support limiting Bristol-Myers Squibb/AstraZeneca’s drug to a subpopulation.